Original language | English (US) |
---|---|
Pages (from-to) | 1892-1894 |
Number of pages | 3 |
Journal | Circulation |
Volume | 140 |
Issue number | 23 |
DOIs | |
State | Published - Dec 3 2019 |
Funding
Dr Mark reports grants from Eli Lilly & Company, Gilead, AstraZeneca, Bristol Myers Squibb, Merck & Company, and Oxygen Therapeutics and consulting fees from Medtronic and Janssen, outside the submitted work. The other authors report no conflicts.
Keywords
- Editorials
- cost effeciveness
- heart failure
- mitral valve insufficiency
- replacement
- ventricular remodeling
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology (medical)